Literature DB >> 18582115

Cinnamoyl inhibitors of tissue transglutaminase.

Christophe Pardin1, Joelle N Pelletier, William D Lubell, Jeffrey W Keillor.   

Abstract

Transglutaminases (TGases) catalyze the intermolecular cross-linking of certain proteins and tissue TGases (TG2) are involved in diverse biological processes. Unregulated, high TGase activities have been implicated in several physiological disorders, but few reversible inhibitors of TG2 have been reported. Herein, we report the synthesis of a series of novel trans-cinammoyl derivatives, discovered to be potent inhibitors of guinea pig liver transglutaminase. The most effective inhibitors evaluated can be sorted into two subclasses: substituted cinnamoyl benzotriazolyl amides and the 3-(substituted cinnamoyl)pyridines, referred to more commonly as azachalcones. Kinetic evaluation of both of these subclasses revealed that they display reversible inhibition and are competitive with acyl donor TGase substrates at IC50 values as low as 18 microM. An analysis of structure-activity relationships within these series of inhibitors permitted the identification of potentially important binding interactions. Further testing of some of the most potent inhibitors demonstrated their selectivity for TG2 and their potential for further development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582115     DOI: 10.1021/jo8004843

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  16 in total

1.  Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.

Authors:  Laila Dafik; Chaitan Khosla
Journal:  Chem Biol       Date:  2011-01-28

Review 2.  Therapeutic approaches for celiac disease.

Authors:  Nicholas M Plugis; Chaitan Khosla
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-05-09       Impact factor: 3.043

Review 3.  Role of transglutaminase 2 in celiac disease pathogenesis.

Authors:  Cornelius Klöck; Thomas R Diraimondo; Chaitan Khosla
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 4.  Regulation of the activities of the mammalian transglutaminase family of enzymes.

Authors:  Cornelius Klöck; Chaitan Khosla
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

5.  Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Xi Jin; Kihang Choi; Chaitan Khosla; Peter B Madrid; Andrew Spencer; Brian C Raimundo; Paul Boardman; Guido Lanza; John H Griffin
Journal:  Bioorg Med Chem Lett       Date:  2010-12-16       Impact factor: 2.823

Review 6.  Novel therapies for coeliac disease.

Authors:  L M Sollid; C Khosla
Journal:  J Intern Med       Date:  2011-06       Impact factor: 8.989

7.  Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.

Authors:  Seon-Hyeong Lee; Nayeon Kim; Se-Jin Kim; Jaewhan Song; Young-Dae Gong; Soo-Youl Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-21       Impact factor: 4.553

Review 8.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

9.  Modulatory Effect of Gliadin Peptide 10-mer on Epithelial Intestinal CACO-2 Cell Inflammatory Response.

Authors:  Antonella Capozzi; Olimpia Vincentini; Pietro Gizzi; Alessandra Porzia; Agostina Longo; Cristina Felli; Vincenzo Mattei; Fabrizio Mainiero; Marco Silano; Maurizio Sorice; Roberta Misasi
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

10.  Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition.

Authors:  Kim Y P Apperley; Isabelle Roy; Vincent Saucier; Nicholas Brunet-Filion; Sara-Pier Piscopo; Christophe Pardin; Élise De Francesco; Catherine Hao; Jeffrey W Keillor
Journal:  Medchemcomm       Date:  2016-12-05       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.